Go Back Cripto-1

Product Detail

Cat # 3081C
Size 5ug
Price $215.00
Qty
Downloads

datasheet.pdf

Cripto plays critical roles during embryogenesis and has been implicated in promoting the growth and spread of tumors. Cripto is required for signaling by certain transforming growth factor-2 superfamily members, such as Nodal, but also antagonizes others, such as activin.

A DNA sequence encoding the human Cripto-1 protein (comprising the signal peptide sequence and the first 139 amino acids of the mature protein, encompassing the EGF-like domain) was expressed in modified human 293 cells.

Cripto-1 is the founding member of the EGF-CFC gene family, which is conserved among vertebrates. Proteins within this family contain a signal sequence, a characteristic EGF-like domain, a cysteine-rich region termed the cryptic (CFC) motif, and a hydrophobic C terminus. It has been reported that Cripto-1 is O fucosylated on Thr-88 and that this modification is required for the physical interaction with Nodal as well as for signalling activity. We have confirmed that Cripto-1B is O-fucosylated at this site. Cripto-1 has been shown to play a critical role in the formation of the primary germ layers during gastrulation, as well as the specification of the anterior-posterior and left-right body axes in early embryonic development. During embryogenesis, cripto-1 functions as an essential co-receptor for nodal, a member of the transforming growth factor beta (TGF beta) family, to mediate transcriptional responses. The overexpression of cripto-1 has been identified in many human cancers, including breast, colon, lung, testicular, stomach, pancreatic, and ovarian cancers. The molecular mechanisms by which cripto-1 promotes tumourigenesis is unknown. However, cripto-1 has been shown to participate in in vitro transformation, migration, invasion, epithelial-to-mesenchymal transition, and branching morphogenesis in mammary epithelial cells and in breast and cervical carcinoma cells. For a review of Cripto-1, please see Strizzi L. et. al. (2005) Oncogene 24(37): 5731- 5741.

We've Moved! Click here for our new address.